Drug-conjugated monoclonal antibodies in advanced/metastatic breast cancer
The goal of this report is to analyze, in a general way, the structure and mechanism of action of drug-conjugated monoclonal (ADC) and examine the studies that led their approval in advanced/metastatic breast cancer (ABC). PubMed, Scopus and SciELO databases were used between 2000 and 2022; Bibliogr...
| Autores: | ; |
|---|---|
| Tipo de documento: | Artículo |
| Estado: | Published version |
| Fecha de publicación: | 2023 |
| País: | Perú |
| Institución: | FIHU |
| Repositorio: | Diagnóstico |
| Lenguaje: | Español |
| OAI Identifier: | oai:revistadiagnostico.fihu.org.pe:article/427 |
| Acceso en línea: | https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/427 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | Anticuerpos monoclonales inmunoconjugados cáncer de mama citostáticos Antibody drug conjugates antibodies monoclonal breast cancer cytostatic agents |
| Sumario: | The goal of this report is to analyze, in a general way, the structure and mechanism of action of drug-conjugated monoclonal (ADC) and examine the studies that led their approval in advanced/metastatic breast cancer (ABC). PubMed, Scopus and SciELO databases were used between 2000 and 2022; Bibliographic references were searched for the keywords associated with ADC and ABC. ADCs combine classical monoclonal assays with a linker and a cytotoxic payload to destroy cancer cells in a targeted manner, when there is internalization of the corresponding receptor. There are currently three ACDs that have been approved for the treatment of CMAM; studies that have demonstrated significant advantages in progression-free survival when compared to standard treatment; evaluation of its main adverse events; implications for its management in our everyday lives; and potential inclusion in the current treatment of CMAM. |
|---|